Overview

Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch

Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
A randomized, evaluator-blinded study to assess skin irritation and skin sensitization of HP-1050 transdermal system (HP-1050) in comparison to XULANE patch in healthy female volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Noven Pharmaceuticals, Inc.